Drug Pipeline

MK-3120 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
4
Recruiting
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-28 NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1)…
date change Primary completion moved earlier: 2030-06-28 -> 2029-02-26
2026-05-28 NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1)…
date change Completion moved earlier: 2030-06-28 -> 2029-02-26
Active Studies by Phase
Phase 1/2
4
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07222488 A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) Bladder Cancer Recruiting
NCT07232602 KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab… Bladder Cancer Recruiting
NCT06818643 A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced… Advanced Solid Tumors Recruiting
NCT05562830 A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1)… Urothelial Carcinoma Recruiting
Sponsors Running MK-3120 Trials
Disease Areas
Get alerts when MK-3120 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free